Loading...
Aspirin is recommended for the prevention and treatment of thrombosis in patients with essential thrombocythemia (ET). However, incomplete suppression of platelet activation by aspirin appears to be common in patients with ET, possibly because the rapidly proliferating megakaryocytes escape from the effects of aspirin given only once every 24 hours. Platelets produced by these megakaryocytes might retain functionality.
To determine what accounts for the failure of aspirin to suppress platelet activation in this setting, an international team of investigators conducted a crossover study in which 21 patients with ET who were taking daily doses of 100 mg aspirin were randomized to receive one of three aspirin regimens: 100 mg twice daily, 200 m…